Objectives To quantify the long-term comparative efficacy and safety of nivolumab in
combination with ipilimumab (NIVO+ IPI) relative to other immunotherapy (IO)-based …

Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung
cancer (NSCLC) accounts for 80–85% of these cases. Surgical resection is the most …

Purpose: Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1)
interaction suppresses local T-cell responses and promotes peripheral tolerance. In the …

Purpose The present study was to investigate the real-world efficacy and safety of anlotinib
monotherapy as third-line therapy for elderly patients with advanced non-small cell lung …

Aim: To estimate the cost-effectiveness of atezolizumab compared with docetaxel and
nivolumab for the treatment of advanced non-small cell lung cancer (NSCLC), as a second …

Aim: To assess the cost–effectiveness of immune checkpoint inhibitors as first-line
treatments for advanced biliary tract cancer (BTC). Methods: This pharmacoeconomic …

Aim To evaluate the cost-effectiveness of first-line treatments, such as erlotinib, gefitinib,
afatinib, dacomitinib, and osimertinib, for patients diagnosed with stage IIIB/IV NSCLC …

Objectives To provide an updated systematic review and meta-analysis of published
randomized controlled trials (RCTs) of the efficacy and safety of programmed cell death 1 …

Squamous cell lung cancer (SqCLC) is the second most common histotype of non-small cell
lung cancer (NSCLC) and is characterized by severe prognosis and lack of specific target …

Network meta-analyses of published clinical trials has received increased attention over the
past years with some meta-analytic publications having had a big impact on the cost-benefit …